Checkpoint inhibitor

Where the papers sit

66 papers from the last 6 months study checkpoint inhibitor directly · updated from PubMed 12 Oct 2026

• Checkpoint Response and Toxicity

  Response prediction is shifting toward integrated tumor, stromal, vascular, and immune features, including VETC patterns, computational pathology, and tumor-microenvironment remodeling. Combinations with TKIs, radiotherapy, chemotherapy, imatinib, hyperthermia, and microbiota-based treatment are being tested to broaden efficacy. Neurotoxicity, myocarditis, cardiac events, and colitis recur as clinically important limits requiring earlier recognition and targeted management. Timing and immune-state effects remain promising but unresolved.

  18 papers · 27.3%

• Tumor Microenvironment Immunotherapy

  Immunotherapy is moving toward active remodeling of the tumor microenvironment rather than relying on checkpoint blockade alone. Macrophage-targeting mRNA lipid nanoparticles, fibroblast-focused models, nucleoside cleavage, and tertiary lymphoid structures represent strategies to improve T-cell access and function. Spatial imaging, radiomics, OMICS, and AI frameworks are being used to identify immune states and predict response. Surgical safety and immune-related colitis remain important translational constraints.

  11 papers · 16.7%

• Lung Cancer Immunotherapy

  Lung cancer treatment is moving toward individualized immunotherapy selection, scheduling, and toxicity management. Immune profiles, kinase activity, LILRB2+ monocytes, ALK status, and BRCA-associated microenvironments are being explored as response markers. Circadian timing may influence survival, but findings remain exploratory and disease-specific. Pre-existing interstitial lung disease and autoimmunity keep pneumonitis and treatment safety central to clinical decisions.

  10 papers · 15.2%

• Real-World Immunotherapy Outcomes

  Real-world evidence is refining how survival, treatment timing, comorbidities, and toxicity shape checkpoint-blockade outcomes. Baseline medications, clonal hematopoiesis, lymph-node dissection, and delayed initiation are being assessed as modifiers of benefit. Severe immune-mediated hepatitis remains a major safety issue, while rechallenge is being studied selectively after recovery. Across gastric, liver, cervical, and other cancers, observational data complement but do not replace randomized evidence.

  7 papers · 10.6%

• Solid Tumor Immunotherapy Outcomes

  Solid-tumor immunotherapy research is linking treatment outcomes with malignant-cell heterogeneity, alternative splicing, aging, and patient-reported quality of life. In head and neck cancer, radiation-related T-cell remodeling and HLA class I loss highlight immune resistance and metastatic variation. Renal cell carcinoma remains a major clinical focus, while perioperative pembrolizumab is being assessed for safety in esophageal cancer. The work is broad and largely characterizes response, resistance, and survivorship rather than establishing one new standard.

  7 papers · 10.6%

• Others — Cancer Immunotherapy Strategies

  Biomarker-guided treatment selection is expanding through tumor mutational burden, whole-exome sequencing, AI pathology, and genomic instability profiling. PARP inhibitors, chemotherapy, and multimodal regimens are being evaluated alongside checkpoint blockade across advanced cancers. Resistance and plasticity remain recurring concerns, including melanoma state changes and hereditary breast-cancer heterogeneity. The evidence is too heterogeneous to establish a single therapeutic direction.

  13 papers · 19.7%